Safety and toxicity of combined oclacitinib and carboplatin or doxorubicin in dogs with solid tumors: a pilot study.

Barrett, Laura E.

Gardner, Heather L.

Barber, Lisa G.

Sadowski, Abbey.

London, Cheryl A.


  • Background: Oclacitinib is an orally bioavailable Janus Kinase (JAK) inhibitor approved for the treatment of canine atopic dermatitis. Aberrant JAK/ Signal Transducer and Activator of Transcription (STAT) signaling within hematologic and solid tumors has been implicated as a driver of tumor growth through effects on the local microenvironment, enhancing angiogenesis, immune suppression, among ... read more
This object is in collection Permanent URL
To Cite:
TARC Citation Guide    EndNote
Detailed Rights